A5022208512- Multiple Myeloma Research and Treatments
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Peripheral Neuropathies and Disorders
- Cancer Treatment and Pharmacology
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Viral-associated cancers and disorders
- Protein Degradation and Inhibitors
- Acute Myeloid Leukemia Research
- Pneumocystis jirovecii pneumonia detection and treatment
- Cutaneous lymphoproliferative disorders research
- Peptidase Inhibition and Analysis
- CNS Lymphoma Diagnosis and Treatment
- Platelet Disorders and Treatments
- Drug-Induced Ocular Toxicity
- Hemoglobinopathies and Related Disorders
- Autoimmune Bullous Skin Diseases
- Vascular Tumors and Angiosarcomas
- Trace Elements in Health
- Ubiquitin and proteasome pathways
- Frailty in Older Adults
- Heparin-Induced Thrombocytopenia and Thrombosis
- Neuroendocrine Tumor Research Advances
Wroclaw Medical University
2015-2024
Szpital Kliniczny Nr 1 we Wrocławiu
2015-2017
Wojskowy Instytut Medycyny Lotniczej
2014
Poznan University of Medical Sciences
2013
The multicenter retrospective study conducted in 38 centers from 20 countries including 172 adult patients with CNS MM aimed to describe the clinical and pathological characteristics outcomes of multiple myeloma (MM) involving central nervous system (CNS). Univariate multivariate analyses were performed identify prognostic factors for survival. median time diagnosis was 3 years. Thirty‐eight (22%) diagnosed involvement at initial 134 (78%) relapse/progression. Upon MM, 97% received therapy...
Skin infiltration in multiple myeloma (skin MM) is a rare clinical problem. Only few cases of skin involvement have been reported, primarily single case reports. We analyzed and present the outcomes, immunohistochemistry cytogenetic features, relevant laboratory data on 53 biopsy-proven MM cases. The median time from diagnosis to was 2 years. There appears be an overrepresentation immunoglobulin class A (IgA) light chain disease MM. found no correlation between CD56 negative infiltration....
POEMS syndrome, a rare plasma cell disorder, is challenging both in the diagnostic and therapeutic management. We present real word retrospective analysis of 108 cases analyzing clinical features modes. compare our results with available literature. This first description such wide use proteasome inhibitors line treatment. (Polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes) syndrome management disease. Currently, literature on sparse most evidence being case reports small...
Light-chain amyloidosis (AL) is a rare multisystem disorder characterized by the deposition of misfolded amyloid fibrils derived from monoclonal immunoglobulin light chains in various organs. One most common organs involved AL heart, with 50-70% patients clinically symptomatic at diagnosis. We conducted multi-center, retrospective analysis 67 diagnosed between July 2012 and August 2022 European modification Mayo 2004 stage III cardiac AL. The important factors identified univariate Cox...
Background: There is an increased risk of second primary malignancies (SMPs) in patients with multiple myeloma (MM). This multinational ‘real-world’ retrospective study analyzed the characteristics and outcomes MM that developed SPMs. Results: 165 were analyzed: 62.4% males; 8.5% a prior cancer; 113 solid SPMs, mainly ≥stage 2; 52 hematological SPM (hemato-SPM), MDS/AML. Patients hemato-SPM younger (p = 0.05) more frequently had AutoHCT 0.012). The time to was shorter older (>65 years)...
Introduction Infections represent one of the most frequent causes death higher-risk MDS patients, as reported previously also by our group. Azacitidine Infection Risk Model (AIR), based on red blood cell (RBC) transfusion dependency, neutropenia <0.8 × 10 9 /L, platelet count <50 albumin <35g/L, and ECOG performance status ≥2 has been proposed retrospective data to estimate risk infection in azacitidine treated patients. Methods The prospective non-intervention study...
Salvage autologous hematopoietic cell transplantation (auto-HCT) may be used to treat relapse of plasma myeloma occurring after previous auto-HCT. When an insufficient number stem cells have been stored from the initial harvest, remobilization is necessary. Here, we aimed analyze efficacy and safety different doses cytarabine (total 800 vs. 1600 2400 mg/m2) for remobilization. Sixty-five patients, 55% male, with a median age at 63 years, were included. Remobilization was performed...
Background: The prognostic value of the comprehensive geriatric assessment (CGA) is recognized by many in hematology. However, there no consensus on utilization alternative abbreviated methods to assess disabilities elderly patients with B-cell non-Hodgkin’s lymphomas (B-NHLs). Aim: aim this study was prospectively analyze selected CGA tools predicting adverse events (AEs) and outcomes R-CHOP or R-CHOP-like treatment diffuse large (DLBCLs) mantle cell (MCLs). Methods: All who participated...
The article focuses on a newly identified group of lymphoproliferative disorders in the 5 th edition WHO classification. These medical issues fall periphery hematologists' daily practice, encompassing primarily rare diseases and those whose diagnosis treatment within purview rheumatology specialists. Despite non-clonal nature described lymphoproliferations, their clinical course can be aggressive, necessitating prompt implementation specialized therapy. primary challenge, however, lies swift...
In multiple myeloma extramedullary involvement occurs in 13% of patients. Central nervous system (CNS) is extremely rare and comprises 1% cases. Review literature shows only limited data on this subject consists mostly few case reports. Scarce knowledge about CNS the course makes its diagnosis treatment very difficult challenging. The authors describe a clinical which illustrates problem from clinician point view. Furthermore, we analyzed available summarized current state diagnosis,...
Multiple myeloma accounting for 10% of malignancies haematopoietic system is a heterogenous disease. In the era individual approach to patient, we are more and interested in distinct features forms this malignancy. article, described rare MM manifestations with reference location (central nervous skin), M-protein produced by tumor cells (biclonal immunoglobulin M), early onset disease (young versus old) pregnancy patients.
The prognostic factors in autotransplanted multiple myeloma (MM) patients with concomitant advanced chronic kidney disease (CKD) are poorly understood, limited, and controversial. We retrospectively analysed 44 MM CKD (eGFR < 40 ml/min), present both at diagnosis autologous stem cell transplantation (ASCT), no improvement of renal function in-between. Patients exhibiting deeper paraprotein responses to pre-transplant treatment predicted better response post ASCT (odds ratio (OR) = 11.6, p...
Myeloma multiplex (MM) is one of the most common haematological malignancies. In recent years, due to new drugs introduction, overall survival patients has improved very much. Nevertheless active ingredients are being searched. There growing attention monoclonal antibodies. Over 20 molecules investigated, but none them already been approved in MM. Work on elotuzumab, daratumumab and bone disease denosumab advanced. this article we describe current state knowledge.
The article is dedicated to pomalidomide efficacy in heavily pretreated patient with a long term history of plasma cell myeloma. We provide the data on effectiveness and safety relapsed refractory